Innovent Biologics (Suzhou) Co. Ltd.

Biotech

Suzhou, Jiangsu, China · Est. 2011

Innovent Biologics is a biopharmaceutical company focused on developing innovative monoclonal antibody therapies for cancer, autoimmune, and infectious diseases.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

207

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

17 drugs in development

Phase 36

Phase 27

Phase 17

By Therapeutic Area

top 6

Oncology

943%

Metabolic & Endocrine

210%

Respiratory

210%

Ophthalmology

210%

Gastroenterology

15%

Immunology

15%

R&D Momentum

79/100

Pipeline Velocity

57/100

Trial Completion Rate

81/100

Pipeline Concentration

24/100

Pipeline Freshness

80/100

Strategic Signals

↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Nov 3, 2026

Active, not recruiting

A Phase II, Open-label, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal and Acral Melanoma Who Had Not Previously Received Systemic Therapy

Oct 28, 2026

Terminated

A Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of IBI356 in Adult Participants With Moderate to Severe Atopic Dermatitis

Earlier

Oct 22, 2026TrialA Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBI3034 Following Single Ascending Dose in Healthy Adults and Multiple Ascending Doses in Participants With Primary IgA Nephropathy

Oct 21, 2026TrialA Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy and Safety of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Oct 20, 2026TrialA Randomized, Double Blind, Placebo Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of IBI3046 in Chinese Participants With Overweight or Obesity

Oct 17, 2026TrialA Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI3011 for Acute Gouty Arthritis

Oct 16, 2026TrialA Multicenter, Randomized, Double-blind, Parallel, and Positive-controlled Phase III Clinical Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis

Oct 6, 2026TrialA Multicenter, Randomized, Double-Blind, Phase III Study of IBI343 Monotherapy Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Participants With Claudin (CLDN) 18.2-Positive, Locally Advanced Unresectable or Metastatic Pancreatic Cancer Who Received>=2 Prior Lines of Therapy

2 more events

Sep 26, 2026TrialA Phase 1 Study of IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Sep 25, 2026TrialA Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Administration of IBI3016 in Japanese Participants With Mild to Moderate Hypertension

Details